Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce R Schackman

Showing results (51-60 of 221) with videos related to

Pageof 23
Sort By:
Pharmacogenomics|November 27, 2015
Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practiceBruce R Schackman, David W Haas, Sanghee S Park, et al.
Health Affairs (Project Hope)|October 2, 2018
Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid PrescriptionsYuhua Bao, Katherine Wen, Phyllis Johnson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 2, 2010
Results from a New York City emergency department rapid HIV testing programKaterina A Christopoulos, Bruce R Schackman, Gunjeong Lee, et al.
Journal of Substance Abuse Treatment|July 23, 2017
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured populationJake R Morgan, Bruce R Schackman, Jared A Leff, et al.
AIDS Patient Care and Stds|February 12, 2008
Sexually active HIV-positive patients frequently report never using condoms in audio computer-assisted self-interviews conducted at routine clinical visitsBruce R Schackman, Zubin Dastur, Quanhong Ni, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 21, 2025
Syringe Services Participants' Preferences for Wound Care, HIV/Hepatitis C Virus Screening, and Opioid Use Disorder Treatment: A Discrete Choice ExperimentRebecca Zimba, Bruce R Schackman, Honoria Guarino, et al.
Journal of Public Health Management and Practice : JPHMP|June 22, 2018
Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment CapacityShashi N Kapadia, Carrie D Johnston, Kristen M Marks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2012
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with menBenjamin P Linas, Angela Y Wong, Bruce R Schackman, et al.
Plos One|February 4, 2016
Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up StrokeAnkur Pandya, Ashley A Eggman, Hooman Kamel, et al.
Journal of Substance Abuse Treatment|August 30, 2017
Monetary conversion factors for economic evaluations of substance use disordersKathryn McCollister, Xuan Yang, Bisma Sayed, et al.
Pageof 23

Showing results (51-60 of 221) with videos related to

Sort By:
Pageof 23
Pharmacogenomics|November 27, 2015
Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practiceBruce R Schackman, David W Haas, Sanghee S Park, et al.
Health Affairs (Project Hope)|October 2, 2018
Assessing The Impact Of State Policies For Prescription Drug Monitoring Programs On High-Risk Opioid PrescriptionsYuhua Bao, Katherine Wen, Phyllis Johnson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 2, 2010
Results from a New York City emergency department rapid HIV testing programKaterina A Christopoulos, Bruce R Schackman, Gunjeong Lee, et al.
Journal of Substance Abuse Treatment|July 23, 2017
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured populationJake R Morgan, Bruce R Schackman, Jared A Leff, et al.
AIDS Patient Care and Stds|February 12, 2008
Sexually active HIV-positive patients frequently report never using condoms in audio computer-assisted self-interviews conducted at routine clinical visitsBruce R Schackman, Zubin Dastur, Quanhong Ni, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 21, 2025
Syringe Services Participants' Preferences for Wound Care, HIV/Hepatitis C Virus Screening, and Opioid Use Disorder Treatment: A Discrete Choice ExperimentRebecca Zimba, Bruce R Schackman, Honoria Guarino, et al.
Journal of Public Health Management and Practice : JPHMP|June 22, 2018
Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment CapacityShashi N Kapadia, Carrie D Johnston, Kristen M Marks, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2012
Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with menBenjamin P Linas, Angela Y Wong, Bruce R Schackman, et al.
Plos One|February 4, 2016
Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up StrokeAnkur Pandya, Ashley A Eggman, Hooman Kamel, et al.
Journal of Substance Abuse Treatment|August 30, 2017
Monetary conversion factors for economic evaluations of substance use disordersKathryn McCollister, Xuan Yang, Bisma Sayed, et al.
Pageof 23